Original reporting and analysis on the stories shaping biotech.
Pfizer is dropping $10 billion on Metsera to crash the obesity drug race, but Wall Street thinks it might be showing up fashionably late to a party that's already in full swing. The deal's clever milestone structure tells you everything about how risky this bet really is.
Eli Lilly just plugged Twist Bioscience's massive antibody libraries into its TuneLab AI platform, building a data flywheel that gets smarter with every experiment. No splashy price tag, but the strategic implications are enormous.
A tiny biotech just dosed the first human with an oral drug designed to attack TDP-43, the rogue protein behind 97% of sporadic ALS cases. It's a target everyone wants to crack and nobody has, which makes this either a breakthrough moment or another chapter in ALS's long history of heartbreak.
Huntington's disease has wrecked every RNA-targeting drug that's tried to crack it. Skyhawk Therapeutics just dropped 15-month data for an oral pill that shows patients actually improving, not just declining slower. The catch? The real test hasn't started yet.
Sling Therapeutics just raised $123 million to develop an oral pill that could replace IV infusions for thyroid eye disease. With Phase 2 data already in hand and a $2 billion market in its sights, this small company is picking a fight with Amgen and Viridian.
Roche just signed a deal worth up to $1 billion with a three-year-old startup that can screen 300,000+ bispecific antibody combinations at once. The real story isn't the price tag; it's what it says about the future of drug discovery.
Novo Nordisk partnered with Anthropic to deploy Claude AI across its drug development pipeline, adding to deals with OpenAI and NVIDIA. The world's most valuable pharma company wants to become 'the most AI-driven healthcare company,' and the broader industry is sprinting to keep up.
GE HealthCare is reportedly in talks to buy radiopharmaceutical developer Sofie Biosciences for ~$1 billion. The deal would let the scanner giant own both the cameras and the film, positioning it at the center of the booming theranostics market.
The FDA's new Operation TrialBlazer pilot wants to cut six to twelve months off early-stage drug development by letting sponsors file IND applications in pieces and run startup steps in parallel. It sounds great on paper, but skeptics wonder if the real bottlenecks are even in FDA's hands.
AstraZeneca is reportedly negotiating a ~$15 billion licensing deal with Summit Therapeutics for ivonescimab, a bispecific antibody that nearly doubled Keytruda's progression-free survival in lung cancer. If it closes, it would be one of the largest pharma licensing agreements ever signed.
Roche just dropped $2.3 billion on a weight-loss drug that doesn't work like any other obesity treatment on the market. Instead of suppressing appetite, HM17321 targets a completely different pathway, one that burns fat while building muscle.
Sionna Therapeutics just axed nearly half its workforce after its lead cystic fibrosis drug produced results indistinguishable from placebo. Now the company is betting everything on a backup plan, and the clock is ticking.
Insilico Medicine's rentosertib just became the first drug fully discovered by AI to enter a pivotal Phase 3 trial. The lung disease study could validate an entire technology, or remind everyone that biology doesn't care who designed the molecule.
Eli Lilly is paying up to $2.875 billion for a four-year-old startup with a Phase 1 drug and $121 million in venture funding. It sounds insane, but Lilly's 12th acquisition of 2026 reveals a deliberate strategy to spend its GLP-1 fortune before competitors catch up.
The FDA just approved the first-ever generic radioligand drug, a copycat of Novartis' blockbuster Lutathera. It's a regulatory first that could crack open pricing and competition in one of oncology's most complex (and expensive) drug categories.
Merck KGaA is spending $11.3 billion to buy Bio-Techne, a toolmaker for drug developers you've probably never heard of. It's the company's biggest deal since Sigma-Aldrich, and it tells you everything about where the life science tools industry is headed.
GSK just dropped $750 million on a preclinical drug from Chimagen Biosciences that won't even enter human trials until 2027. In the most crowded corner of blood cancer, the pharma giant is betting a trispecific antibody can outdo a packed field of approved therapies.
The FDA just approved the first-ever mRNA flu vaccine, and it's not just about the flu. Moderna's mFlusiva could reshape how we make seasonal vaccines, ditch the decades-old egg-based process, and prove mRNA is a platform, not a pandemic fluke.
Eli Lilly pulled the plug on an early-stage obesity drug, and Wall Street barely flinched. When you see what the company is building instead, you'll understand why this might be the savviest move in pharma right now.
A tiny biotech just posted obesity data using a mechanism that once destroyed careers. Corbus Pharmaceuticals' CB1-blocking pill showed clean weight loss where the industry's biggest players stumbled, and the implications for the post-GLP-1 era are bigger than the company's market cap.
BioNTech's experimental drug gotistobart nearly doubled overall survival compared to chemotherapy in one of lung cancer's toughest-to-treat subtypes. The result could reshape second-line treatment for squamous NSCLC and rewrite BioNTech's identity as an oncology company.
The FDA held a landmark public hearing on psychedelic therapy access and safety, and it wasn't asking *if* these drugs should be approved. It was asking *how*. With Compass Pathways' psilocybin potentially months from a historic first approval, the real debate is just getting started.
Join thousands of biotech professionals who start their day with our free, daily briefing.